Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial

Steven E. Nissen, Ricardo E. Dent-Acosta , Robert S. Rosenson, Erik Stroes, Naveed Sattar, David Preiss, G. B. John Mancini, Christie M. Ballantyne, Alberico Catapano, Ionna Gouni-Berthold, Evan A. Stein, Allen Xue, Scott M. Wasserman, Rob Scott, Paul D. Thompson, GAUSS-3 Investigators, Sam Lehman, Michel Krempf, Chantal Bully, Peter BosiljanoffElisabeth Steinhagen-Thiessen, Paolo Pintus, Claudio Borghi, Tiziana Sampietro, Giovanni Battista Vigna, Elmo Mannarino, Claudio Pozzi, Anho Liem, Rudolf Van Leendert, Russell Scott, Thorbjorn Kjaernli, Gisle Langslet, Andrew Jacovides, Eric Klug, Dirk Blom, Dermot Neely, Charlotte Dawson, Michael Miller, Kevin McCullum, Michael Rocco, Prediman Shah, Norman Lepor, Paul Rosenblit, Gregory Pokrywka, Michael Blazing, Peter Toth, Patrick Moriarty, Melvyn Rubenfire, Pamela Morris, Arshed Quyyumi, Stephen Kopecky

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences